Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus

Journal of Diabetes Research

Volumn 2013, Issue , 2013, Pages

  Skrha J ^a,a   Soupal J ^a   Loni Ekali, G ^b   Prazny M ^a   Kalousova M ^a   Kvasnicka J ^a   Landova L ^a   Zima, T ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Ayos District Hospital   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; AGED; ALBUMINURIA; ARTICLE; AUTOFLUORESCENCE; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84879330523     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2013/650694     Document Type: Article

References (35)

1. Genuth S., Sun W., Cleary P., Sell D. R., Dahms W., Malone J., Sivitz W., Monnier V. M., Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005 54 11 3103 3111 2-s2.0-33644698951 10.2337/diabetes.54.11.3103 (Pubitemid 43334362)
2. Brownlee M., The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005 54 6 1615 1625 2-s2.0-20044376702 10.2337/diabetes.54. 6.1615 (Pubitemid 40770750)
3. Zieman S. J., Melenovsky V., Clattenburg L., Corretti M. C., Capriotti A., Gerstenblith G., Kass D. A., Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. Journal of Hypertension 2007 25 3 577 583 2-s2.0-33846849277 10.1097/HJH.0b013e328013e7dd (Pubitemid 46213796)
4. Giardino I., Edelstein D., Brownlee M., Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. Journal of Clinical Investigation 1994 94 1 110 117 2-s2.0-0028304845
5. Hofmann M. A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., Avila C., Kambham N., Bierhaus A., Nawroth P., Neurath M. F., Slattery T., Beach D., McClary J., Nagashima M., Morser J., Stern D., Schmidt A. M., RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999 97 7 889 901 2-s2.0-0033603241 10.1016/S0092-8674(00) 80801-6 (Pubitemid 29375048)
6. Haslbeck K. M., Schleicher E., Bierhaus A., Nawroth P., Haslbeck M., Neundörfer B., Heuss D., The AGE/RACE/NF- B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Experimental and Clinical Endocrinology and Diabetes 2005 113 5 288 291 2-s2.0-20944442173 10.1055/s-2005-865600 (Pubitemid 40868185)
7. Yao D., Brownlee M., Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010 59 1 249 255 2-s2.0-77449142258 10.2337/db09-0801
8. Bierhaus A., Nawroth P. P., Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009 52 11 2251 2263 2-s2.0-70349859675 10.1007/s00125-009-1458-9
9. Yan S. F., Yan S. D., Ramasamy R., Schmidt A. M., Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Annals of Medicine 2009 41 6 408 422 2-s2.0-70349877740 10.1080/07853890902806576
10. Katakami N., Matsuhisa M., Kaneto H., Matsuoka T. A., Sakamoto K., Yasuda T., Yamasaki Y., Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diabetes and Vascular Disease Research 2008 5 3 190 197 2-s2.0-51749105625 10.3132/dvdr.2008.031
11. Yan S. F., Ramasamy R., Schmidt A. M., Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochemical Pharmacology 2010 79 10 1379 1386 2-s2.0-77649186801 10.1016/j.bcp.2010.01.013
12. Vazzana N., Santilli F., Cuccurullo C., Davì G., Soluble forms of RAGE in internal medicine. Internal and Emergency Medicine 2009 4 5 389 401 2-s2.0-71449100255 10.1007/s11739-009-0300-1
13. Monnier V. M., Bautista O., Kenny D., Sell D. R., Fogarty J., Dahms W., Cleary P. A., Lachin J., Genuth S., Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA(1c) as markers of diabetic complications. Diabetes 1999 48 4 870 880 2-s2.0-0032997958 (Pubitemid 29153089)
14. Chiarelli F., De Martino M., Mezzetti A., Catino M., Morgese G., Cuccurullo F., Verrotti A., Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. Journal of Pediatrics 1999 134 4 486 491 2-s2.0-0033510738 (Pubitemid 30180632)
15. Meerwaldt R., Lutgers H. L., Links T. P., Graaff R., Baynes J. W., Gans R. O. B., Smit A. J., Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007 30 1 107 112 2-s2.0-33845989105 10.2337/dc06-1391 (Pubitemid 46052507)
16. Münch G., Keis R., Weßels A., Riederer P., Bahner U., Heidland A., Niwa T., Lemke H. D., Schinzel R., Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA1. European Journal of Clinical Chemistry and Clinical Biochemistry 1997 35 9 669 677 2-s2.0-0030698699
17. Meerwaldt R., Graaf R., Oomen P. H. N., Links T. P., Jager J. J., Alderson N. L., Thorpe S. R., Baynes J. W., Gans R. O. B., Smit A. J., Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004 47 7 1324 1330 2-s2.0-4143113592 (Pubitemid 39093330)
18. Sattar N., Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities. Diabetic Medicine 2012 29 5 13
19. Monami M., Lamanna C., Gori F., Bartalucci F., Marchionni N., Mannucci E., Skin autofluorescence in type 2 diabetes: beyond blood glucose. Diabetes Research and Clinical Practice 2008 79 1 56 60 2-s2.0-37549047955 10.1016/j.diabres.2007.07.007
20. Mulder D. J., Van De Water T., Lutgers H. L., Graaff R., Gans R. O., Zijlstra F., Smit A. J., Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation end-products: an overview of current clinical studies, evidence, and limitations. Diabetes Technology and Therapeutics 2006 8 5 523 535 2-s2.0-33845602222 10.1089/dia.2006.8.523 (Pubitemid 44946877)
21. Yonekura H., Yamamoto Y., Sakurai S., Petrova R. G., Abedin M. J., Li H., Yasui K., Takeuchi M., Makita Z., Takasawa S., Okamoto H., Watanabe T., Yamamoto H., Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochemical Journal 2003 370 3 1097 1109 2-s2.0-0037444761 10.1042/BJ20021371 (Pubitemid 36399105)
22. Haim M., Tanne D., Boyko V., Reshef T., Goldbourt U., Leor J., Mekori Y. A., Behar S., Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease: data From the Bezafibrate Infarction Prevention (BIP) Study. Journal of the American College of Cardiology 2002 39 7 1133 1138 2-s2.0-0037012405 10.1016/S0735- 1097(02)01728-X (Pubitemid 34267415)
23. Widlansky M. E., Gokce N., Keaney J. F., Vita J. A., The clinical implications of endothelial dysfunction. Journal of the American College of Cardiology 2003 42 7 1149 1160 2-s2.0-0141504305 10.1016/S0735-1097(03)00994-X (Pubitemid 37188333)
24. Levey A. S., Bosch J. P., Lewis J. B., Greene T., Rogers N., Roth D., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Annals of Internal Medicine 1999 130 6 461 470 2-s2.0-0033574249 (Pubitemid 29135798)
25. Nienhuis H. L., De leeuw K., Bijzet J., Smit A., Schalkwijk C. G., Graaff R., Kallenberg C. G., Bijl M., Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation end-products. Rheumatology 2008 47 10 1554 1558 2-s2.0-52949115717 10.1093/rheumatology/ken302
26. Mulder D. J., van Haelst P. L., Gross S., de Leeuw K., Bijzet J., Graaff R., Gans R. O., Zijlstra F., Smit A. J., Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 2008 197 1 217 223 2-s2.0-39449097303 10.1016/j.atherosclerosis. 2007.03.027 (Pubitemid 351273241)
27. Humpert P. M., Djuric Z., Kopf S., Rudofsky G., Morcos M., Nawroth P. P., Bierhaus A., Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovascular Diabetology 2007 6, article 9 2-s2.0-33947386181 10.1186/1475-2840-6-9 (Pubitemid 46443939)
28. Kalousová M., Jáchymová M., Oto M., Hodková M., Kazderová M., Tesař V., Zima T., Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrology Dialysis Transplantation 2007 22 7 2020 2026 2-s2.0-34547830269 10.1093/ndt/gfm050 (Pubitemid 47244776)
29. Gerrits E. G., Lutgers H. L., Kleefstra N., Graaff R., Groenier K. H., Smit A. J., Gans R. O., Bilo H. J., Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 2008 31 3 517 521 2-s2.0-44449155477 10.2337/dc07-1755
30. Gerrits E. G., Lutgers H. L., Kleefstra N., Groenier K. H., Smit A. J., Gans R. O., Skin advanced glycation end product accumulation is poorly reflected by glycemic control in type 2 diabetic patients (ZODIAC-9). Journal of Diabetes Science and Technology 2008 2 572 577
31. Furth A. J., Glycated proteins in diabetes. British Journal of Biomedical Science 1997 54 3 192 200 2-s2.0-0030813477 (Pubitemid 27445269)
32. de Groot L., Hinkema H., Westra J., Smit A. J., Kallenberg C. G. M., Bijl M., Advanced glycation end-products are increased in rheumatoid arthritis patients with controlled disease. Arthritis Research & Therapy 2011 13, article R205
33. Kalousova M., Hodkova M., Kazderova M., Fialova J., Tesar V., Dusilova-Sulkova S., Soluble receptor for advanced glycation end products in patients with decreased renal function. American Journal of Kidney Diseases 2006 47 406 411 (Pubitemid 43255173)
34. Kankova K., Kalousova M., Hertlova M., Krusova D., Olsovsky J., Zima T., Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene. Archives of Physiology and Biochemistry 2008 114 111 119 (Pubitemid 351892711)
35. Lutgers H. L., Gerrits E. G., Graaff R., Links T. P., Sluiter W. J., Gans R. O., Bilo H. J., Smit A. J., Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 2009 52 5 789 797 2-s2.0-64149085518 10.1007/s00125-009-1308-9